Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Ilya TsimafeyeuPavel BorisovAhmed AbdelgafurRoman LeonenkovOlga NovikovaIrina GusevaMarina DemchenkovaNadezhda MikhailovaAndrey SemenovZakhar YurmazovIrina SivunovaMadina RamazanovaSergey GamayunovDmitry KosovGennady BratslavskyPublished in: Targeted oncology (2020)
The encouraging PFS and favorable safety profile observed in the FavorAx study support the administration of axitinib in mRCC patients with favorable IMDC risk and a history of prior sunitinib or pazopanib.